Food and Drug Administration Approves Groundbreaking Gene Therapy for Advanced Alzheimer's Disease
Federal health regulators have granted accelerated approval to a novel genetic therapy proven to significantly slow cognitive decline in patients with early-stage Alzheimer's disease, offering major medical breakthroughs while sparking national debates over the estimated one million United States dollar price tag.